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Background: Iron involvement/imbalance is strongly suspected in multiple sclerosis (MS) etiopathogenesis, but its
role is quite debated. Iron deposits encircle the veins in brain MS lesions, increasing local metal concentrations in
brain parenchyma as documented by magnetic resonance imaging and histochemical studies. Conversely, systemic
iron overload is not always observed. We explored the role of common single nucleotide polymorphisms (SNPs) in
the main iron homeostasis genes in MS patients.
Methods: By the pyrosequencing technique, we investigated 414 MS cases [Relapsing-remitting (RR), n=273;
Progressive, n=141, of which: Secondary (SP), n=103 and Primary (PP), n=38], and 414 matched healthy controls.
Five SNPs in 4 genes were assessed: hemochromatosis (HFE: C282Y, H63D), ferroportin (FPN1: -8CG), hepcidin (HEPC:
-582AG), and transferrin (TF: P570S).
Results: The FPN1-8GG genotype was overrepresented in the whole MS population (OR=4.38; 95%CI, 1.89-10.1;
P<0.0001) and a similar risk was found among patients with progressive forms. Conversely, the HEPC -582GG
genotype was overrepresented only in progressive forms (OR=2.53; 95%CI, 1.34-4.78; P=0.006) so that SP and PP
versus RR yielded significant outputs (P=0.009). For almost all SNPs, MS disability score (EDSS), severity score (MSSS),
as well as progression index (PI) showed a significant increase when comparing homozygotes versus individuals
carrying other genotypes: HEPC -582GG (EDSS, 4.24±2.87 vs 2.78±2.1; P=0.003; MSSS, 5.6±3.06 vs 3.79±2.6; P=0.001);
FPN1-8GG (PI, 1.11±2.01 vs 0.6±1.31; P=0.01; MSSS, 5.08±2.98 vs 3.85±2.8; P=0.01); HFE 63DD (PI, 1.63±2.6 vs 0.6
±0.86; P=0.009). Finally, HEPC -582G-carriers had a significantly higher chance to switch into the progressive form
(HR=3.55; 1.83-6.84; log-rank P=0.00006).
Conclusions: Polymorphisms in the genes coding for iron binding and transporting proteins, in the presence of
local iron overload, might be responsible for suboptimal iron handling. This might account for the significant
variability peculiar to MS phenotypes, particularly affecting MS risk and progression paving the way for personalized
pharmacogenetic applications in the clinical practice.* Correspondence: d.gemmati@unife.it
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Multiple sclerosis (MS) is the leading cause of disability
in young and middle-aged people in the developed
world. It is an inflammatory, demyelinating disease of
the central nervous system (CNS), and is widely consid-
ered to have an autoimmune etiology. The multistep
mechanism of the disease involves inflammation, demye-
lination, and neurodegeneration [1].
A growing body of evidence, supported by both post-
mortem studies and advanced MRI techniques, shows
increased CNS iron stores in MS patients, particularly in
the sub-cortical gray matter [2-5]. The hypotheses of iron
excess as a cause of oxidative stress [6,7], with possible
contribution to neuronal injury and death, has been com-
monly proposed in other neurodegenerative disorders
[5,8,9]. Indeed, iron level manipulation has been reported
as being neuroprotective and neurorestorative in neurode-
generative diseases [10]. Moreover, it was demonstrated
that iron deficiency provides protection from the develop-
ment of experimental autoimmune encephalomyelitis, the
animal model of MS [11].
A contribution to the development of iron-driven
oxidative stress in several degenerative disorders is
linked to the presence of one or more genetic variants
leading to suboptimal iron balance in the tissue
[5,9,12-14]. Some of the main genes and single nucleo-
tide polymorphisms (SNPs) involved in iron manage-
ment with possible effects on tissue injury are
described below.
The HFE gene, locus 6p21.3, codes for a membrane
protein similar to MHC class I-type proteins. This pro-
tein modulates iron absorption by regulating the inter-
action of the transferrin receptor with transferrin, and
defects in this gene cause hereditary hemochromatosis
[15]. C282Y and H63D are the two commonest disease-
associated variants in the HFE gene, and iron-dependent
inflammation seems to be influenced by both poly-
morphisms [12-15]. Apart from hemochromatosis,
C282Y increases the risk of iron-dependent skin lesions
and affects wound healing in patients with leg iron over-
load due to chronic venous diseases [14,16]. Among
neurodegenerative disorders, the HFE gene has been
investigated as a modulator of the different clinical phe-
notypes. In the field of MS, controversial data have been
published; C282Y was found to be overrepresented
among MS cases of North-Western European origin
[17], and it was considered a predictor for early onset, as
well as the H63D homozygotes or the H63D/C282Y
compound heterozygotes [18]. Other groups did not find
any significant association, when comparing MS cases
with low versus high disability scores [19]. Nevertheless,
the C282Y variant has recently been considered a mar-
ker of poorer MS prognosis and it has been associated
with MS aggressiveness [20].The FPN1 gene, locus 2q32.2, codes for a multiple trans-
membrane domain protein. Its official name is Solute Car-
rier Family 40 (iron-regulated transporter), member 1
(SLC40A1). Differently from other iron transporters, it is
the only identified mammalian molecule that exports iron
outside the cell [21]. FPN1 expression is finely tuned by
the iron responsive element (IRE) in the 5’untranslated re-
gion (5’UTR) of mRNA, which, under cell iron overload-
ing, increases protein expression leading to iron exports.
Four SNPs and one CGG microsatellite repeat in the
FPN1 gene have been studied in relation to HFE [22]. Two
of these, -8CG and -98GC, are close to the IRE element
and are in complete linkage disequilibrium. To date, no
data are available about the role of FPN1 gene variants in
MS susceptibility or in other neurodegenerative disorders,
and very few data have been reported on their potential
role on other iron overload diseases [16].
The HEPC gene, locus 19q13.1, codes for a 25-amino-
acid peptide, derived from cleavage of an 84-amino-acid
long pro-peptide, which is mainly synthesized by hepato-
cytes [23]. Its official name is Hepcidin Anti-Microbial
Peptide (HAMP), and it is a major regulator of iron bal-
ance acting by binding to the FPN1 protein on cell
membrane, suppressing it. A polymorphism in the pro-
moter region (−582AG) has recently been described as
possibly associated with iron metabolism [24-26], but no
data on the HEPC gene variants and neurodegenerative
diseases are reported so far.
The TF gene, locus 3q22.1, codes for a molecule that
forms a stable complex with the HFE protein facilitating
iron transfer via transferrin receptor [27]. The effect of HFE
on iron absorption depends on its relationship with the
transferrin receptor: HFE variants affect TF binding, deter-
mining a loss of HFE-repressor function for TF uptake,
thereby increasing iron transport within the cells. A com-
mon variant in the TF gene is the P570S (TF, C1C2) [28].
The role of the C2 allele in iron balancing [28,29] and in
neurodegenerative diseases [30,31] has been debated; none-
theless, a joint effect of the HFE and TF genes, responsible
for a greater synergic effect, suggested possible gene-gene
and gene-environment interactions [32].
Considering that little is known and that there are
controversial data about the role of iron trafficking genes
in the natural history of MS, we decided to investigate
whether common functional SNPs within the main iron
genes might contribute to MS susceptibility, onset, dis-
ability/severity, and progression.
Methods
Patients and controls
A total of 414 unrelated patients (female/male = 264/
150) affected by clinically definite MS, according to the
revised criteria of McDonald [33], and classified accord-
ing to the criteria of Lublin [34] as having relapsing-
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(SP), n=103, and Primary (PP), n=38] courses, were en-
rolled in the study. They were consecutively selected
from the patient population of two MS Centres, both
placed in Northern Italy (Ferrara/Bologna, n=265;
Novara, n=149). Clinical disability and severity were re-
spectively scored using Kurtzke’s Expanded Disability
Status Scale (EDSS) and MS Severity Score (MSSS) [35].
The duration of the disease was expressed in years from
the date of neurological diagnosis. The progression index
(PI), defined as the ratio between EDSS/MS duration,
was assessed in the entire MS group. The control group
consisted of 414 healthy volunteers matched for age,
gender, and geographic origin with the MS patients; con-
trol subjects were without any sign or familial history for
neurological diseases.
The study was approved by the local Ethical Commit-
tee and all the recruited subjects signed an informed
consent to participate to the study.
DNA extraction, PCR conditions, and sequencing
DNA was isolated from peripheral frozen whole blood by
the automated DNA extraction and purification robot
(BioRobot EZ1 system from QIAGEN; Hilden, Germany),
which performs purification of nucleic acids using a mag-
netic bead technology.
HFE, FPN1, HEPC, and TF SNPs were genotyped in
the entire case–control cohort by PCR amplifying the
relevant genomic region using specific couple of primers
and the lyophilic complete UNIVERAL MASTER MIX
kit (STAT-NAT DNA-Mix; SENTINEL Diagnostics,
Milan, Italy). In all cases, the PCR thermal profile was as
follows: 94°/30sec; 57°/30sec; 72°/60sec; x 33 cycles.
PCRs were performed in a PTC-200 thermal cycler
(M. J. Research, Inc., Watertown, MA, USA). SNPs
detection was performed by pyrosequencing using the
Pyromark ID System (Biotage AB Uppsala, Sweden)
according to the standard procedures for amplicon
denaturation, purification, and sequencing. Table 1
shows the primer sequences needed to amplify/sequence
the target gene. All the oligo sequences of the SNPs
investigated (Forward, Reverse and Sequence primers)
were selected to have at least 98.0% compatibility score.
Genotype confirming procedure
Haplotypes were confirmed by re-genotyping about 20%
of randomly selected samples among each different geno-
type group for each specific polymorphism by means of
enzymatic restriction of PCR amplicons. Table 1 shows
the restriction enzymes utilized (New England Biolabs
Inc., Hitchin, UK), the digestion fragments obtained, and
the specific temperature for each different restricted
amplicon. All the digestion reactions were carried out
according to the Supplier’s instructions. There were nodiscrepancies between genotypes determined in duplicate
and/or by different methods. Known genotypes were used
as control references.
Statistical analysis
Statistical differences among groups were assessed by the
Student’s t-test and the Chi-squared test, respectively, for
mean values and genotype distribution comparisons.
When appropriate, Yates' correction or Fisher's exact test
was applied. Adjusted Odds Ratios (OR) and 95% confi-
dence intervals (95%CI), calculated by logistic regression
models, were used to estimate the risk associated with MS
and to the different subtypes in the presence of the rare
homozygous condition (e.g. FPN1 -8GG, HFE 63DD,
HEPC -582GG, and TF 570SS) or heterozygous (HFE
282CY) condition compared to the remaining genotypes
(i.e. heterozygous and/or homozygous for the common al-
lele). The model accounted for sex and age distribution
between cases and healthy controls. P values are presented
both as uncorrected (if ≤ 0.05) and as corrected for mul-
tiple testing (Bonferroni correction).
Power estimates indicated that, if each analyzed poly-
morphism (disease allele frequency of 10%) was to dir-
ectly confer a 1.5 to 2-fold increase in the relative risk of
MS, the case/control cohort used in this research would
be of sufficient size to have 76 to 100% power to detect
a significant association at the 0.05 level (the power
decreases to 54 and 99% for α=0.01).
Survival curves were constructed by the Kaplan-Meier
method, and survival among groups was compared using
the Log-Rank test and the associated risk values were
examined using a Cox-proportional hazard model. The
end-point was the date of starting progression or the
tenth year of follow-up, whichever came first.
All analyses were performed by using Systat V.5.0
(Systat Inc., Evanston, IL, USA) and the SPSS Statistical
Package (SPSS Inc., Chicago, IL, USA).
Results
Population characteristics
The clinical and demographic characteristics in the
whole MS group, in the MS subgroups, and in healthy
controls are shown in Table 2. As expected, progressive
course had significantly higher EDSS, PI, and MSSS
when compared to the RR subgroup. Progressive cases
had significant longer disease duration and higher mean
age at recruitment. Accordingly, they showed the highest
PI value, whilst the other clinical findings were not sig-
nificantly different among subgroups.
SNP genotypes and MS susceptibility
All the investigated SNP genotypes were distributed
according to the Hardy-Weinberg equilibrium in both
case and healthy control groups.
Table 1 Primer sequences and restriction-product characteristics
Oligo name Oligo sequence PCR size (bp) Restriction enzyme Restriction products (bp)
FNP1 -8CG
Fw R/P 5’CCAGTTCCTTGCACTCCTG-3’ 129 BstUI (60°C) 85+44 (Pol)
Rv R/P 5’CATCCTCTCTGGCGGTTG-3’ [Bio]
Sq 5’AGAGCCAGCGGGGTC-3’
HFE C282Y
Fw R 5’-TGGCAAGGGTAAACAGATCC-3’ 387 RsaI (37°C) 247+140 (wt)
Rv R 5’-CTCAGGCACTCCTCTCAACC-3’
Fw P 5’-CGAACCTAAAGACGTATTGCC-3’
Rv P 5’-CCCAATAGATTTTCTCAGCTCCT-3’ [Bio]
Sq 5’GGAAGAGCAGAGATATACG-3’
HFE H63D
Fw R 5’-ACATGGTTAAGGCCTGTTGC-3’ 207 BclI (50°C) 137+70 (Pol)
Rv R 5’-GCCACATCTGGCTTGAAATT-3’
Fw P 5’-CCACATCTGGCTTGAAATTCT-3’
Rv P 5’-GTTTGAAGCTTTGGGCTACG-3’ [Bio]
Sq 5’GGGCTCCACACGGCG-3’
TF P570S
Fw R 5’-GCTGTGCCTTGATGGTACCAGGTAA-3’ 110 BstEII (60°C) 89+21 (wt)
Rv R 5’-GGACGCAAGCTTCCTTATCT-3’
Fw P 5’-GAAAAAGACTATGAGTTGCTGTGC-3’
Rv P 5’-CTGTGACCACAGCGTGATTC-3’ [Bio]
Sq 5’-TGATGGTACCAGGAA-3’
HEPC -582AG
Fw R 5’-ACCCTCCTGCCTTGGCCTC-3’ 252 HpyCH4IV (37°C) 226+26 (Pol)
Rv R 5’-CCATTGCTTTAAGCTCTCACC-3’
Fw P 5’-ACATCTCAAGGGTCTGACACTGG-3’
Rv P 5’-GAGCAGGGCAAGCATCAGC-3’ [Bio]
Sq 5’-TCTGACACTGGGAAAAC-3’
Fw and Rv indicate the forward and reverse primer, respectively; Sq indicates the sequencing primer; R and P indicate Restriction and Pyrosequencing technique,
respectively; WT and Pol, indicate the wild-type (common) and polymorphic (rare) allele, respectively; [Bio], indicate the biotinylated primer.
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ciated ORs computed in the total MS patients and in the
clinical subtypes compared to healthy controls or, when
specified, to the RR subgroup.
Globally, the rate of FPN1 -8GG homozygotes was
7.0% in MS cases and 1.7% in controls. This yielded an
overall OR of 4.38 (95%CI, 1.89-10.1; P<0.0001) when
compared with the rest of genotypes. Among RR and
Progressive cases computed together (SP + PP), the
assessed risks were similar to that of the entire MS
population (OR=4.35; 95%CI, 1.8-10.5; P<0.0001, and
OR=4.21; 95%CI, 1.57-11.28; P=0.003, respectively). Fi-
nally, no comparisons showed a significant difference in
genotype distribution between RR and Progressive cases.
As far as HFE gene polymorphisms are concerned,
H63D yielded ORs>1 in all the considered subgroups,
though far from statistical significance. C282Y yielded
non-significant ORs≤1 in many of the consideredsubgroups. Significant ORs were not found in combined
analyses computing C282Y/H63D double carriers, neither
in the whole nor in the subgroups (data not shown).
Considering the HEPC -582AG variant, significant risk
values were restricted to the Progressive group, when
compared either with healthy controls (OR=2.53; 95%CI,
1.34-4.78; P=0.006) or RR cases (OR=2.68; 95%CI, 1.32-
5.45; P=0.009). Although we do not show data in detail,
we evidenced that the risk further increased among PP
patients with values higher than 4-fold (OR=4.4; 95%CI,
1.83-10.5; P=0.001). Due to the scanty number of PP cases
in our study, all the related results could be featured by
chance, nevertheless, it is noteworthy a clear stepwise
trend of GG homozygote frequency from RR (5.5%), to SP
(10.7%), to PP (21.1%). This yielded a significant over-
representation of GG homozygotes among the whole Pro-
gressive group (13.5%) when compared to controls (5.8%;
P=0.006) or RR sub-group (5.5%; P=0.009). It could be
Table 2 Patients’ and healthy controls’ characteristics
Whole group RR PP + SP Healthy controls
(n=414) (n=273) (n=141) (n=414)
female/male 264/150 179/94 85/56 264/150
♀ (%) (63.77 %) (65.56%) (60.3%) (63.77 %)
Age, yy ± SD 42.0±11.0 38.5±9.51 48.5±10.40* 42.0±11.0
(range) (16.0-72.0) (17.0-70.0) (16.0-72.0) (16.0-72.0)
onset, yy ± SD 32.37±10.37 31.65±10.31 33.17±10.21 – –
(range) (11.0-61.0) (14.0-61.0) (11.0-55.0)
Duration, yy ± SD 9.14±7.43 6.92±6.47 13.44±7.34* – –
(range) (0.2-50.0) (0.2-50.0) (0.2-35.0)
EDSS ± SD 2.91±2.24 1.8±1.04 5.03±2.43* – –
(range) (1.0-10.0) (1.0-7.0) (1.0-10.0)
PI ± SD 0.63±1.08 0.59±0.94 0.72±1.32* – –
(range) (0.03-10.0) (0.03-10.0) (0.04-10.0)
MSSS ± SD 3.94±2.74 2.93±1.99 5.98±2.87* – –
(range) (0.13-9.99) (0.13-9.6) (0.29-9.99)
*P<0.0001, when compared to the RR group. Values shown are mean, standard deviation (SD), and (ranges).
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at increased risk for progression.
No risk association was found considering the TF P570S
gene variant, in the whole as well as in the different sub-
groups considered, though appreciable ORs>1 were found.
The Bonferroni correction, applied to the genotype
comparison, confirmed all the significances obtained in
the uncorrected analysis (Table 3).
When allelic comparisons were performed, the signifi-
cant overrepresentation of the rare allele in patients was
completely retained for each SNP investigated and in
every group/subgroup resembling those of the genotype.
However, after Bonferroni correction the number of sig-
nificances was cut down (Table 4).
SNPs genotypes and MS clinical characteristics (single
analyses)
Table 5 shows the clinical characteristics (age of onset, dis-
ease duration, EDSS, PI, and MSSS) in the whole group of
MS patients stratified by the different SNP genotypes.
FPN1 -8GG homozygotes had a slightly higher mean
EDSS score when compared with the rest of genotypes
(3.59±2.43 vs 2.85±2.45; P=0.045). Although a trend
among the three different genotypes was observed, it did
not reach significance (P-trend= 0.07). The same EDSS
comparisons yielded indeed higher significant differences
in the RR subgroup (2.59±2.12 vs 1.74±0.88; P=0.0006; P-
trend= 0.01). Similarly, considering PI, FPN1 -8GG homo-
zygotes had a significantly higher index when compared
with the remaining genotypes (1.11±2.01 vs 0.59±0.97;
P=0.01) and the significant trend among genotypes was
maintained, as well as PI comparisons among the RRsubgroup (1.08±2.2 vs 0.55±0.76; P=0.01; P-trend=0.03).
MSSS significantly rose among the -8GG homozygotes in
the whole (5.08±2.98 vs 3.85±2.7; P=0.01), as well as in the
RR subgroup (4.02±2.99 vs 2.85±1.87; P=0.01).
HFE polymorphisms showed PI and MSSS values sig-
nificantly related to the H63D gene variant exclusively in
the whole group. Accordingly, by comparing 63DD
homozygotes with the remaining cases, PI was signifi-
cantly higher (1.63±2.6 vs 0.59±0.99; P=0.009) as well as
MSSS did (5.33±3.03 vs 3.89±2.72; P=0.03). Concerning
the HFE C282Y polymorphism, none of the clinical
characteristics were significantly related with particular
genotypes. This was very likely due to the rarity of 282Y
carriers (e.g. no 282YY homozygotes, were found).
The HEPC -582AG variant had a higher mean EDSS
value among -582GG homozygotes compared with
the other genotypes (4.24±2.87 vs 2.78±2.18 P=0.003).
Similarly, MSSS showed higher values among GG-
homozygotes (5.6±3.06 vs 3.79±2.65; P=0.001).
Conversely, PI values did not reach significant changes
(P=0.08), as well as further sub-analyses.
TF P570S in our study population did not affect at sig-
nificant extent any clinical finding, neither in the whole,
nor in the subgroups.
Interestingly, an unexpected, significant delay in onset
(about 6-yy) was observed among HEPC −582 G-carriers
respect to non carriers (35.11±10.3 vs 29.57±9.86;
P<0.0001). A similar behaviour, though at a lesser extent,
and restricted just to homozygotes, was observed among
the HFE H63D variant (36.1±8.23 vs 32.24±10.11; P=0.06).
Finally, disease duration did not show significant dif-
ferences either in the whole or in the subset groups.
Table 3 Genotype distributions and related OR values
FPN1-8CG HFE H63D HFE C282Y HEPC -582AG TF P570S
Genotypes (%) CC CG GG HH HD DD CC CY AA AG GG PP PS SS
All cases (n=414) 244 (58.9) 141 (34.05) 29 (7.0) 288 (69.6) 113 (27.3) 13 (3.15) 401 (96.9) 13 (3.1) 205 (49.5) 175 (42.27) 34 (8.2) 278 (67.15) 122 (29.5) 14 (3.4)
OR (95%CI) 4.38 (1.89-10.1) 1.65 (0.67-4.01) 0.76 (0.36-1.58) 1.45 (0.85-2.5) 1.3 (0.6-2.86)
P uncorrected P<0.0001 (NS) (NS) (NS) (NS)
(P corrected) (P<0.0004)
RR (n=273) 162 (59.3) 92 (33.7) 19 (7.0) 190 (69.6) 77 (28.2) 6 (2.2) 266 (97.4) 7 (2.6) 144 (52.75) 114 (42.0) 15 (5.5) 189 (69.2) 75 (27.5) 9 (3.3)
OR (95%CI) 4.35 (1.8-10.5) 1.1 (0.4-3.32) 0.61 (0.25-1.5) 0.94 (0.49-1.83) 1.25 (0.51-3.05)
P uncorrected P<0.0001 (NS) (NS) (NS) (NS)
(P corrected) (P<0.0004)
PP + SP (n=141) 82 (58.2) 49 (34.7) 10 (7.14) 98 (69.5) 36 (25.5) 7 (4.9) 135 (95.7) 6 (4.3) 61 (43.3) 61 (43.3) 19 (13.5) 89 (63.1) 47 (33.3) 5 (3.5)
OR (95%CI) 4.21 (1.57-11.28) 2.65 (0.94-7.45) 1.04 (0.4-2.69) 2.53 (1.34-4.78) 1.35 (0.46-3.95)
P uncorrected P=0.003 (NS) (NS) P=0.006 (NS)
(P corrected) (P=0.012) (P=0.024)
OR1 (95%CI) 1.02 (0.46-2.26) 2.32 (0.77-7.05) 1.69 (0.56-5.12) 2.68 (1.32-5.45) 1.08 (0.35-3.28)
P uncorrected (NS) (NS) (NS) P=0.009 (NS)
(P corrected) (P=0.036)
Controls (n=414) 278 (67.1) 129 (31.2) 7 (1.7) 305 (73.7) 101 (24.4) 8 (1.9) 397 (95.9) 17 (4.1) 238 (57.5) 152 (36.7) 24 (5.8) 280 (67.6) 123 (29.7) 11 (2.7)
All OR calculations are obtained computing the rare homozygous genotype vs the rest of genotypes comparing cases vs controls. OR1 is referred to the Progressive group in which the reference category is the RR
subgroup. Corrected and uncorrected P-values are respectively referred to the presence/absence of Bonferroni correction. NS, not significant.
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Table 4 Allelic distributions and related OR values
FPN1-8CG HFE H63D HFE C282Y HEPC-582AG TF P570S
Allele (%) C G H D C Y A G P S
All subjects
(n=828)
629 (76.0) 199 (24.0) 689 (83.2) 139 (16.8) 802 (96.86) 26 (3.14) 585 (70.6) 243 (29.3) 678 (81.9) 150 (18.1)
OR (95%CI) 1.52 (1.2-1.93) 1.23 (0.94-1.6) 0.76 (0.45-1.27) 1.30 (1.05-1.62) 1.04 (0.81-1.34)
P uncorrected <0.0001 NS NS 0.020 NS
(P corrected) (<0.002) (NS) (NS) (NS) (NS)
RR (n=546) 416 (76.2) 130 (23.8) 457 (83.7) 89 (16.3) 532 (97.4) 14 (2.6) 402 (73.6) 144 (26.4) 453 (83.0) 93 (17.0)
OR (95%CI) 1.5 (1.15-1.95) 1.18 (0.88-1.6) 0.61 (0.33-1.16) 1.12 (0.88-1.44) 0.97 (0.73-1.29)
P uncorrected 0.004 NS NS NS NS
(P corrected) (NS) (NS) (NS) (NS) (NS)
PP + SP (n=282) 213(75.5) 69 (24.5) 232 (82.3) 50 (17.7) 270 (96.86) 12 (3.14) 183 (64.9) 99 (35.1) 225 (79.8) 57 (20.2)
OR (95%CI) 1.55 (1.12-2.15) 1.31 (0.91-1.88) 1.04 (0.53-2.03) 1.7 (1.27-2.27) 1.19 (0.85-1.68)
P uncorrected 0.010 NS NS <0.0001 NS
(P corrected) (NS) (NS) (NS) (<0.002) (NS)
OR1 (95%CI) 1.03 (0.74-1.45) 1.10 (0.75-1.61) 1.7 (0.8-3.7) 1.51 (1.11-2.06) 1.23 (0.86-1.78)
P uncorrected NS NS NS 0.010 NS
(P corrected) (NS) (NS) (NS) (NS) (NS)
Controls (n=828) 685 (82.7) 143 (17.3) 711 (85.9) 117 (14.1) 794 (95.9) 34 (4.1) 628 (75.9) 200 (24.1) 683 (82.5) 145 (17.5)
All OR calculations are obtained computing the rare vs the common allele comparing cases vs controls. OR1 is referred to the Progressive group in which the
reference category is the RR subgroup. Corrected and uncorrected P-values are respectively referred to the presence/absence of Bonferroni correction. NS, not
significant.
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characteristics (combined case–control analysis)
In attempt to calculate a cumulative MS risk associated
with the coexistence of multiple predisposing genotypes,
we compared the whole group of cases and controls car-
rying a combination of at least four risk alleles in at least
two different SNPs (multi-carriers) with subjects who
were homozygous for the common allele in all the con-
sidered gene variants (fully wild-types). Combined
homozygotes at least in two different SNPs, single
homozygotes in one and combined carriers in at least
two, or carrying at least a quadruple heterozygous condi-
tion, they globally were 12.1% in patients (n=50) and
5.1% in controls (n=21). Conversely, the fully wild-type
condition was 11.4% in cases (n=47) and 17.9% in con-
trols (n=74). Strongly significant risk-values were
obtained from this kind of comparison, suggesting a
hypothetical cumulative risk measurability (OR=3.74;
CI95%, 2.0-7.02; P<0.0001), although no synergistic
effects were recorded.
Combined intra-case analysis
Similarly, to verify the effects of the combined carrier
condition on MS, we stratified all the clinical character-
istics investigated by multi-carrier genotype conditions.
We found that the combined carrier patients had higher
mean values of EDSS (3.65±2.71 vs 2.07±1.5; P=0.0007),
PI (1.0±1.4 vs 0.35±0.45; P=0.006), and MSSS (5.06±2.9
vs 2.7±2.12; P=0.0007) when compared with the fullywild-type patients (Table 6). Accordingly, in the com-
bined carriers mean EDSS increased about 1.8-fold,
mean PI 2.86-fold, and mean MSSS 1.9-fold.
Retrospective survival analysis among SP and RR patients
In order to verify the hypothesis that MS patients carry-
ing the HEPC -582G-allele might be at increased risk for
progression, we calculated among the 103 SP patients,
how long they stayed within the previous and less severe
clinical phenotype (i.e. the RR condition) before they
switched towards the severest SP condition, and this was
stratified by the SNPs investigated. HEPC -582AG
showed an extraordinary output, ascribing to the G-
allele the role of earlier progression-switch. In detail, after
a retrospective observational analysis of ten years,
patients carrying the -582G-allele had a higher chance to
progress into the SP-phenotype of almost 3-fold
(HR=2.77; 1.45-5.34; log-rank P=0.001) if compared to
patients carrying the -582AA counterpart genotype. This
partial observation prompted us to also include in the
survival analysis all the RR patients (n=273), totally ana-
lyzing 376 MS patients (Figure 1). The overall HR was
greatly improved (HR=3.55; 1.83-6.84; log-rank
P=0.00006). Among the other analyzed SNPs, no similar
results or combined effects were observed.
An additional indirect result in favour of this hypoth-
esis was obtained by comparing the RR mean disease
duration among the three different genotypic classes.
Again, -582GG patients showed the shortest disease
Table 5 Clinical findings stratified by SNPs in the whole group of patients
FPN1 -8CG Onset Duration EDSS PI MSSS
−8CC 33.5±9.8 9.3±7.35 2.73±2.07 0.58±0.78 3.72±2.66
(n=244) (11.0-60.0) (0.3-38.0) (1.0-10) (0.03-7.0) (0.13-9.99)
−8CG 31.92±10.45 9.32±7.95 3.07±2.48 0.64±1.24 4.09±2.78
(n=141) (14.0-61.0) (0.2-50.0) (1.0-9.0) (0.03-10) (0.15-9.97)
−8GG 33.38±12.3 7.0±5.17 3.59±2.43 1.11±2.01 5.08±2.98
(n=29) (15.0-53.0) (0.2-20.4) (1.0-9.0) (0.1-10.0) (0.78-9.97)
P uncorrected NS 0.05 0.045 0.01 0.01
(P corrected) (0.05) (0.05)
HFE C282Y
282CC 32.3±10.37 9.19±7.49 2.9±2.25 0.63±1.07 3.9±2.73
(n=401) (11.0-60.0) (0.2-50.0) (1.0-10) (0.03-10.0) (0.13-9.99)
282CY 33.62±11.12 7.27±5.35 3.16±2.21 0.58±1.54 4.64±2.91
(n=13) (16.0-61.0) (1.0-27.0) (1.0-9.0) (0.13-1.3) (1.13-9.92)
P-value NS NS NS NS NS
HFE H63D
63HH 32.75±10.94 8.92±7.12 2.89±2.23 0.62±0.98 3.99±2.78
(n=288) (11.0-61.0) (0.2-50.0) (1.0-10) (0.03-10) (0.15-9.99)
63HD 30.97±8.94 9.8±8.2 2.81±2.21 0.55±1.01 3.65±2.55
(n=113) (14.0-56.0) (0.5-38.0) (1.0-9.0) (0.03-10) (0.13-9.97)
63DD 36.1±8.23 8.43±7.57 3.96±2.93 1.63±2.6 5.33±3.03
(n=13) (28.0-55.0) (0.2-22.2) (1.0-8.5) (0.2-7.5) (1.28-9.99)
P uncorrected 0.06 NS NS 0.009 0.03
(P corrected) (NS) (0.045) (NS)
HEPC -582AG
−582AA 29.57±9.86 9.54-7.3 2.59±2.06 0.57±.1.14 3.39±2.56
(n=205) (14.0-61.0) (0.2-38.0) (1.0-9.0) (0.03-10) (0.13-9.97)
−582AG 35.1±9.92 8.78±7.78 3.01±2.22 0.63±0.94 4.26±2.7
(n=175) (11.0-56.0) (0.2-50.0) (1.0-9.0) (0.04-10.0) (0.29-9.98)
−582GG 35.2±11.56 8.55±6.45 4.24±2.87 0.96±1.38 5.6±3.06
(n=34) (20.0-56.0) (0.5-27.0) (1.0-10) (0.13-7.0) (1.13-9.99)
P uncorrected 0.07* NS 0.003 0.08 0.001
(P corrected) (NS) (0.015) (NS) (0.005)
TF P570S
570PP 32.38±10.44 8.42±6.97 2.72±2.15 0.69±1.26 3.78±2.66
(n=278) (11.0-56.0) (0.2 34.0) (1.0-10) (0.03-10.0) (0.15-9.99)
570PS 32.32±10.53 11.08±8.24 3.38±2.41 0.48±0.52 4.28±2.92
(n=122) (14.0-61.0) (0.5-50.0) (1.0-9.0) (0.03-4.0) (0.13-9.97)
570SS 32.53±8.43 6.52±6.17 2.47±2.05 0.77±0.89 4.1±2.52
(n=14) (21.0-51.0) (0.5-22.0) (1.0-9.0) (0.15-3.0) (1.13-9.73)
P uncorrected NS 0.06 NS NS NS
(P corrected) (NS)
Values shown are mean, standard deviation (SD), and (ranges). All P-values shown are obtained computing the rare homozygous genotype vs the rest of
genotypes. *Computing G-carriers vs AA-genotype P-value <0.0001. Significant P-values, and those <0.10 are reported. NS, not significant.
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the number of the -582G allele increased (RR, n=273)
(GG, 4.52y±3.6 < AG, 6.2y±5.6 < AA, 7.8y±6.8;
P=0.007). Similarly to the previous survival analysis, wealso included the RR durations of the SP patients (RR +
SP; n=376). Accordingly, the significance strongly
increased (GG, 4.21y±3.9 < AG, 7.45y±5.9 < AA, 9.12y
±7.7; P=0.0005; Figure 2).
Table 6 Clinical finding comparisons between multi-carriers and fully wild-types
Onset Duration EDSS PI MSSS
Multi-carriers (n=50) 36.23±9.09 (20–53) 7.83±6.42 (1.0-22) 3.65±2.71 (1.0-9.0) 1.0±1.4 (0.09-4.0) 5.06±2.9 (0.85-9.97)
Fully wild-types (n=47) 33.26±10.39 (16–55) 8.78±5.57 (0.5-24) 2.07±1.5 (1.0-7.5) 0.35±0.45 (0.07-2.24) 2.7±2.12 (0.45.-8.64)
P uncorrected NS NS 0.0007 0.006 0.0007
(P corrected) (0.0035) (0.03) (0.0035)
Multi-carriers (patients carrying at least four rare alleles in at least two different genes) and fully wild-types (homozygous patients for the common allele in all the
considered genes) are as defined in the Results section. Values shown are mean, standard deviation (SD), and (ranges). NS, not significant.
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In order to check any gender-related association between
MS and the SNPs, we contextually analyzed clinical findings
and susceptibilities by gender in every SNP investigated. The
main noteworthy combinations are reported below.
Among SP male patients, a 9-fold MS susceptibility in-
crease (OR=8.56; 95%CI, 2.03-36.1; P=0.003) was asso-
ciated with FPN1 -8GG genotype.
Among Progressive female patients computed together
(PP + SP), a high MS susceptibility increase (OR=6.02; 95%
CI, 1.1-33.49; P=0.04) was associated with the HFE 63DD
genotype. It is to note that females had higher risk also in
the whole MS group (OR=3.81; 95%CI, 0.95-20.01; P=0.05).
Finally, among Progressive male patients computed to-
gether (PP + SP), a 5-fold MS susceptibility increase
(OR=4.9; 95%CI, 1.9-12.5; P=0.001) was associated with
the HEPC -582GG genotype.
Discussion
Several issues surround iron and neurodegenerative dis-
ease, due to the fact that iron is essential in neuronal cell
life, yet brain iron accumulation can be toxic [5,7-9].Figure 1 Survival analysis among 376 MS patients (SP + RR; n=103+2
status among MS patients was significantly different when stratified by HEP
secondary progressive MS course among G-carriers (dashed line) (HR=3.55;Iron imbalance is strongly suspected in MS pathogen-
esis, even though there is no evidence that systemic iron
overload occurs more frequently in MS patients than in
general population [36,37].
In contrast, at the brain level, susceptibility weighted
imaging MRI techniques permit to reliably measure iron
in the brain and to follow the natural history of iron ac-
cumulation. Interestingly, a correlation exists between
iron storages and disability, manifested either by cogni-
tive or motor symptoms, suggesting a role in the com-
plex mosaic of MS pathogenesis [38-41].
The exact underlying mechanism by which brain iron
accumulates in CNS of MS patients is not fully under-
stood. Iron enters into the brain through the blood–
brain-barrier, due to iron transport proteins expressed
locally [42] and it is stored according to the efficiency of
the transferring receptors. This can be controlled at the
post-transcriptional level by iron regulatory proteins
(IRPs) that interact with IRE motifs on mRNA to alter
the expression on brain endothelial cells, neurons, glia,
oligodendrocytes, and macrophages [43,44]. When there
is not enough iron in the milieu, IRPs bind IRE motifs to73) stratified by the HEPC -582AG SNP. The survival trend of the RR
C SNP. The comparison yields an increased chance to progress in the
1.83-6.84; log-rank P=0.00006).
Figure 2 Mean ± SD (standard deviation) disease duration (years) among 376 MS patients (SP + RR; n=103+273) stratified by the HEPC
SNP. The comparison between the HEPC genotype conditions yields significant differences (i.e. G-carriers have shorter mean duration time).
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roportin and increase that of the transferrin receptor,
favouring mRNA stability. Basically, this allows the cell
to uptake more iron to efficiently use it before it bounds
to the storage protein ferritin [43]. In the literature there
are two main hypotheses on the mechanism leading to
iron accumulation in brain parenchyma in course of MS.
The first is linked with microglia and astrocyte iron ac-
cumulation in course of unknown steps linked with neu-
rodegeneration [5,9,44]. The second is linked with a
vascular condition, known as chronic cerebrospinal ven-
ous insufficiency (CCSVI) related to reduced brain per-
fusion [45]. It has been hypothesized that CCSVI might
favourite erythrocytes diapedesis, and subsequent iron
deposition [12,13,38,46]. Even though this is an intri-
guing and interesting hypothesis and a genetic depend-
ence of CCSVI has recently been described by our group
[47], other authors do not directly link CCSVI with
increased iron and MS [48-50].
Therefore, in spite of the lack of concordance between
blood and brain iron levels, whatever the mechanism
causing brain iron deposition is, the same group of pro-
teins regulate iron influx, efflux and storage [42,51]. We
hence looked at the commonest SNPs in the main iron-
protein genes.
The main finding of our study was an increased MS
susceptibility risk, of more than 4-fold, associated with
the FPN1 -8GG homozygous genotype. In addition,
stratifying disease progression and severity by FPN1 gen-
otypes, PI and MSSS gradually increased as the number
of the G alleles increased, ascribing to the GG-genotype
the highest value. This suggests that MS patients carry-
ing the -8G-allele might be at increased risk for disease
worsening. These results can really be considered noveland peculiar findings in the field of MS since, to date,
FPN1 SNPs have been only associated with particular
diseases, such as venous leg ulcers [16], or reinvestigated
as genetic modifiers of HFE [22]. FPN1 expression is
regulated at different levels: by the IRE sequence in the
5’-UTR that, interacting with the IRPs, finely tunes how
many FPN1 molecules can be expressed [43]; and post-
translationally by the hepatic hormone hepcidin [23].
The IRE region, results in increased/reduced FPN1 ex-
pression respectively under high/low cellular iron, lead-
ing to personalized iron export. Hepcidin interacts and
blocks FPN1 in the presence of high iron levels. Gener-
ally, FPN1 mutations return a molecule that cannot
reach the cell surface or block FPN1 internalization and
degradation affecting both hepcidin interaction and iron
export. The strong closeness of FPN1 -8CG to the cru-
cial IRE region, prompted us to investigate its role in
MS. The significant associations we found can be specu-
latively interpreted as a direct role on the IRE-IRP inter-
actions, or as an indirect role of still unknown molecular
defects in linkage with the SNP. In CNS cells, or in
macrophages, these situations may potentially affect
iron-balancing, similarly as described for the HFE
C282Y [52]. Micro-deletions in the IRE region lead to
expected increased in FPN1 levels despite low cellular
iron levels, and to date no mutations specifically affect-
ing IRE have been identified in the FPN1 gene [53].
Our second relevant finding was related to the HEPC
gene. Homozygous -582GG cases had an increased MS
susceptibility of about 2.5-fold among progressive
patients and the risk was kept when progressive cases
were compared to the RR course. In addition, EDSS pro-
gressively increased among the three different HEPC
genotypes, with homozygotes about 1.5-higher than the
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gotes was higher among progressive cases (13.5%) when
compared to RR group (5.5%), who retained the same
rate observed among healthy controls (5.8%). This could
suggest that those patients might have rapid disease pro-
gression and/or higher chance for progression. Though
confounding, due to the unavoidable presence of a great
proportion of RR who will develop secondarily the pro-
gressive clinical course, this result could even be under-
estimated, because of the few homozygotes found
among RR could even decrease after progression, and
improve the statistical comparison. To verify the hypoth-
esis, we split the group of SP cases (n=103) in those
with/without the -582G-allele in order to calculate how
long these two subgroups stayed in the previous less se-
vere clinical phenotype before becoming progressive. In-
deed, during a ten-year retrospective analysis, those
carriers had a 3-fold higher chance to progress in the
SP-phenotype if compared to the counterpart -582AA
genotype. Similarly, including in the same survival ana-
lyses also the RR patients, those carriers had a 4-fold
higher chance to progress. If this was true, the comple-
mentary analysis, that is computing together the mean
duration time of the RR-patients (n=273) and that of the
previous RR status of the 103 SP patients (total, n=376),
could indirectly confirm this hypothesis by yielding op-
posite results (i.e. -582AA-carriers show a longer disease
duration). That is exactly what we observed (GG, 4.52y
±3.6 < AG, 6.2y±5.6 < AA, 7.8y±6.8); a possible explan-
ation is that SP G-carriers could have faster left the RR
condition to switch in the progressive form. Therefore,
the RR G-carriers could have a potential shorter mean
duration time within the less severe condition (GG,
4.21y±3.9 < AG, 7.45y±5.9 < AA, 9.12y±7.7). We
recognize the intrinsic limit of these partial and indirect
results, but all are in favour of an earlier-progression-
switch role ascribable to the HEPC polymorphism. Con-
flicting and scanty results exist on the -582AG HEPC
variant [24,25]. The G-allele decreases the transcrip-
tional activity by 20% respect to the A-allele in HepG2
cells in the presence of upstream stimulatory factor 1
(USF1) and by 12-14% with USF2 [26]. The Authors
concluded that the promoter variant is not associated
with serum iron parameters and that the in-vitro studies
resulted in little reductions of the G-allele mediated
trans-activation. Although they ascribed to the HEPC
variant negligible in-vivo effects, we state that, regardless
the small change in the promoter activity between the
two alleles, this could be enough to have significant det-
rimental effects on long-staying iron overload as is the
case in MS patients. Accordingly, also subtle chronic
lower HEPC expressions in subjects with -582G-allele
may be responsible for significant local iron dysregula-
tion mostly in homozygous GG-patients. We previouslyreported that even minor SNP effects (i.e. those found in
MMP12 -82AG) had significant results in another de-
generative disease under chronic iron-overload condi-
tions [16].
As far as the HFE gene is concerned, H63D and
C282Y did not reveal in our population associations with
MS. One exception was the 3-fold higher PI found
among the 63DD-homozygotes. However, also in other
studies the role of the HFE gene in MS, seems not to be
particularly decisive, being often controversial [17-20].
HLA-DR15 is associated with younger age of onset in
MS [54], though we found an appreciable delayed onset
among HFE63 DD-Homozygotes. This could be
explained by speculating that iron greedy-cells (i.e. those
with the polymorphism) could even be protective, para-
doxically helping myelin synthesis in the early phases of
the disease [55]. After iron moves on insoluble-hemosi-
derin, iron-starved cells cannot use it, this favours en-
ergy crisis and cell apoptosis [5,9,56]. Similarly, this
could also be speculated for the HEPC variant, in which
G-carriers show delayed onset.
Controversial results exist in the association between
TF P570S and Alzheimer disease (AD) [30,31], hypothe-
sizing a not definitively demonstrated defect in total iron
binding capacity [28,29] and a suggestive synergism be-
tween TF and HFE gene variants and AD [32]. We did
not find such a synergism in MS, except a non-
significant higher MSSS among the TF 570S-carriers.
Gender appears to play critical role in development,
progression and treatment of MS. In addition, higher
brain iron level was found associated with male gender
in presence of common iron gene SNPs [57,58]. For this
reason, we performed a gender-related sub-analysis, and
we found different risk associations related to the differ-
ent SNPs considered, but definite results cannot be
drawn due to the low number of patients obtained after
subanalyses. Clarifying a possible differential gender-
associated risk to develop neurodegenerative diseases,
combining genetic and MRI biomarkers, may help clini-
cians to design primary intervention programs to select
high-risk sub-groups.
We conclude that, all the SNPs investigated work in
the same direction: potential iron dysregulation, oxida-
tive tissue damage, and possible actions on MS [51].
This was the reason we looked at the combined effect
that the coexistence of several at risk-alleles might have
on MS. The fact that among multi-carriers the risk
increased, as well as disability, progression, and severity
did, strongly implies the multi-gene nature of iron un-
balancing in MS.
We recognize that the main limitation of our study is
linked to the low number of investigated SNPs. A relevant
number of SNPs exist in other candidate genes related to
tissue inflammation and degeneration. A further
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with the lack of knowledge still present in MS pathogen-
esis as well as in the steps leading to iron accumulation.
Conclusions
Whatever the mechanism causing brain iron deposition
is, our study shows strong influence of gene variants in
MS onset and disease course in terms of expectation of
disability and severity. Although, in our survey the
homozygous prevalence of the investigated SNPs is low,
ranging from 3% to 8%, we have to take into account
that more than 80% of our patients carry at least one of
these variants, and that about 50% are double carrier.
On the basis that, combined carriers can have pheno-
typic effects greater than or comparable to single homo-
zygotes, and that iron homeostasis is multi-genetically
tuned, this opens new clinical concrete perspectives in
monitoring iron accumulation as an underlying mechan-
ism connected to the natural history of MS together
with the prognostic value of iron trafficking genes.
People carrying at risk alleles could be selected in ad-
vance for therapeutic trials aimed to iron chelation and
dietary modification in the view that MS course could
be in part genetically targeted. So, further larger investi-
gations on iron genes should become mandatory in MS.
Understanding the exact mechanism by which iron acts
in the brain causing MS and how the brain would be
impacted by iron chelation/supplementation could po-
tentially furnish precious prognostic information and
novel insights for alternative personalized treatments
(pharmacogenetics) aimed in preventing or counteract-
ing neuron loss and degeneration.
All this is in line with a recently published review, on
the importance of individualised therapy in MS, based
on genetic and biochemical determinations [59].
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